NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 45,481 shares of NewAmsterdam Pharma stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $35.31, for a total value of $1,605,934.11. Following the sale, the insider directly owned 53,500 shares of the company's stock, valued at $1,889,085. This trade represents a 45.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Johannes Jacob Piete Kastelein also recently made the following trade(s):
- On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total value of $199,500.00.
NewAmsterdam Pharma Stock Performance
Shares of NASDAQ NAMS opened at $36.01 on Wednesday. The stock's 50-day simple moving average is $34.02 and its 200-day simple moving average is $32.85. The firm has a market capitalization of $4.08 billion, a PE ratio of -20.81 and a beta of 0.06. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $42.00.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The company had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.92 million. On average, sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.
Institutional Investors Weigh In On NewAmsterdam Pharma
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Farther Finance Advisors LLC boosted its stake in shares of NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company's stock worth $25,000 after buying an additional 708 shares during the period. Mather Group LLC. purchased a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at approximately $30,000. Wells Fargo & Company MN increased its holdings in shares of NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company's stock valued at $32,000 after purchasing an additional 300 shares during the period. Finally, Navalign LLC purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $46,000. 89.89% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on NAMS. Wall Street Zen cut shares of NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a research report on Saturday. The Goldman Sachs Group raised their price objective on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a "neutral" rating in a report on Tuesday, December 2nd. Cantor Fitzgerald reissued an "overweight" rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Royal Bank Of Canada upped their target price on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Wednesday, January 21st. Finally, HC Wainwright upgraded NewAmsterdam Pharma to a "strong-buy" rating in a research note on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.00.
Get Our Latest Stock Report on NewAmsterdam Pharma
NewAmsterdam Pharma Company Profile
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
